- Lung cancer therapy including novel compounds and early phase trials
- Breast cancer therapeutics including novel compounds and early phase trials
- Health services research
- Economics of lung cancer therapy
- Treatment decision-making in advanced cancer, including development of patient decision aids
- Patient-physician communication
Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer.
Curr Oncol. 2019 Feb;26(1):e81-e93
Clin Lung Cancer. 2018 Dec 22;:
The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer.
Curr Treat Options Oncol. 2019 Feb 18;20(3):21
Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer.
Clin Lung Cancer. 2018 Dec 19;:
Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.
Cancer. 2019 Feb 15;:
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study.
Eur J Cancer. 2019 Jan 24;109:28-35
Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials.
Eur J Cancer. 2018 Dec 06;107:1-7
The role of cytology in molecular testing and personalized medicine in lung cancer: A clinical perspective.
Cancer Cytopathol. 2018 Dec 04;:
Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma.
Oncologist. 2018 Nov 26;:
Curr Oncol. 2018 Oct;25(5):e385-e390
Associate Professor, Department of Medicine, University of Toronto
President, Lung Cancer Canada
Chair, Working Group on Economic Analysis, National Cancer Institute of Canada Clinical Trials Group